NIAID awards $1.4M for further development of HIV assay

07/23/2013 | Genetic Engineering & Biotechnology News

MBio Diagnostics landed a two-year, $1.4 million grant from the National Institute of Allergy and Infectious Diseases for the next development phase of a low-cost, point-of-care HIV antigen/antibody diagnostic test. Infectious disease specialists at the University of California, San Diego, are assisting with development. The company's pipeline includes diagnostics for tuberculosis and the hepatitis C virus.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX